Table 2 Numbers of patients positive on each ESSDAI domain and positive for moderate/high activity on each domain as a function of level of treatment with PSL
Patients with positive activity level | Patients with moderate/high activity level | ||||
|---|---|---|---|---|---|
All patients (n = 31) | High/medium dose PSL (n = 12) | No/low dose PSL (n = 19) | High/medium dose PSL (n = 12) | No/low dose PSL (n = 12) | |
ESSDAI domain | |||||
Constitutional | 18 | 9 (50.0%) | 9 (50.0%) | 5 | 4 |
Lymphadenopathy | 9 | 3 (33.3%) | 6 (66.7%) | 1 | 0 |
Glandular | 10 | 5 (50.0%) | 5 (50.0%) | 4 | 0 |
Articular | 9 | 4 (44.4%) | 5 (55.6%) | 1 | 0 |
Cutaneous | 9 | 6 (66.7%) | 3 (33.3%) | 2 | 2 |
Pulmonary | 0 | 0 | 0 | 0 | 0 |
Renal | 1 | 1 (100%) | 0 | 0 | 0 |
Muscular | 0 | 0 | 0 | 0 | 0 |
PNS | 2 | 2 (100%) | 0 | 1 | 0 |
CNS | 3 | 3 (100%) | 0 | 3 | 0 |
Hematological | 3 | 2 (66.7%) | 1 (33.3%) | 2 | 1 |
Biological | 18 | 10 (55.6%) | 8 (44.4%) | 9 | 7 |